Price T Rowe Associates Inc Biotechnology

Price T Rowe Associates Inc

$867 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$35.4B	$3.39 Billion 0.39% of portfolio	5,516,894	Q4 2024 Reduced 5.22%
REGN Regeneron Pharmaceuticals, Inc.	$72.2B	$1.49 Billion 0.17% of portfolio	2,085,447	Q4 2024 Added 63.53%
INSM Insmed Inc	$10.7B	$877 Million 0.1% of portfolio	12,704,410	Q4 2024 Added 0.98%
ALNY Alnylam Pharmaceuticals, Inc.	$31.6B	$781 Million 0.09% of portfolio	3,319,385	Q4 2024 Reduced 3.84%
TECH Bio Techne Corp	$2.59B	$767 Million 0.09% of portfolio	10,654,267	Q4 2024 Added 13.05%
VRTX Vertex Pharmaceuticals Inc	$118B	$681 Million 0.08% of portfolio	1,690,700	Q4 2024 Reduced 4.37%
NVO Novo Nordisk A S	$176B	$546 Million 0.06% of portfolio	6,345,118	Q4 2024 Reduced 33.79%
BGNE Bei Gene, Ltd.	$23.5B	$543 Million 0.06% of portfolio	2,937,170	Q4 2024 Added 8.78%
BPMC Blueprint Medicines Corp	$5.61B	$495 Million 0.06% of portfolio	5,679,089	Q4 2024 Added 5.42%
SRRK Scholar Rock Holding Corp	$1.91B	$401 Million 0.05% of portfolio	9,283,421	Q4 2024 Added 7.27%
PCVX Vaxcyte, Inc.	$4.98B	$325 Million 0.04% of portfolio	3,966,956	Q4 2024 Reduced 11.18%
RNA Avidity Biosciences, Inc.	$1.68B	$321 Million 0.04% of portfolio	11,042,823	Q4 2024 Added 3.84%
ASND Ascendis Pharma A/S	$8.04B	$314 Million 0.04% of portfolio	2,283,207	Q4 2024 Added 7.64%
CRNX Crinetics Pharmaceuticals, Inc.	$1.89B	$277 Million 0.03% of portfolio	5,414,505	Q4 2024 Added 9.5%
KYMR Kymera Therapeutics, Inc.	$2.02B	$276 Million 0.03% of portfolio	6,870,333	Q4 2024 Added 3.38%
RVMD Revolution Medicines, Inc.	$3.57B	$257 Million 0.03% of portfolio	5,865,962	Q4 2024 Added 10.4%
LEGN Legend Biotech Corp	$6.1B	$222 Million 0.03% of portfolio	6,808,081	Q4 2024 Reduced 39.03%
VERA Vera Therapeutics, Inc.	$743M	$185 Million 0.02% of portfolio	4,377,049	Q4 2024 Added 11.12%
MDGL Madrigal Pharmaceuticals, Inc.	$5.77B	$182 Million 0.02% of portfolio	588,764	Q4 2024 Reduced 19.75%
MLTX Moon Lake Immunotherapeutics	$1.61B	$181 Million 0.02% of portfolio	3,343,643	Q4 2024 Added 12.19%
ACLX Arcellx, Inc.	$2.79B	$163 Million 0.02% of portfolio	2,121,322	Q4 2024 Added 11.61%
UTHR United Therapeutics Corp	$16.9B	$140 Million 0.02% of portfolio	397,882	Q4 2024 Added 15.49%
IONS Ionis Pharmaceuticals Inc	$4.41B	$134 Million 0.02% of portfolio	3,826,939	Q4 2024 Reduced 9.1%
REPL Replimune Group, Inc.	$695M	$133 Million 0.02% of portfolio	10,962,883	Q4 2024 Added 10.97%
CYTK Cytokinetics Inc	$4.35B	$123 Million 0.01% of portfolio	2,625,081	Q4 2024 Reduced 17.06%
AKRO Akero Therapeutics, Inc.	$2.35B	$120 Million 0.01% of portfolio	4,321,972	Q4 2024 Added 13.49%
SWTX Spring Works Therapeutics, Inc.	$3.58B	$118 Million 0.01% of portfolio	3,274,786	Q4 2024 Reduced 6.87%
SMMT Summit Therapeutics Inc.	$4.3B	$117 Million 0.01% of portfolio	6,557,927	Q4 2024 Added 20.56%
RARE Ultragenyx Pharmaceutical Inc.	$2.98B	$106 Million 0.01% of portfolio	2,512,423	Q4 2024 Reduced 18.13%
NUVL Nuvalent, Inc.	$3.35B	$102 Million 0.01% of portfolio	1,297,910	Q4 2024 Added 19.92%
IDYA Ideaya Biosciences, Inc.	$1.01B	$99.4 Million 0.01% of portfolio	3,866,908	Q4 2024 Reduced 3.7%
XNCR Xencor Inc	$974M	$92.8 Million 0.01% of portfolio	4,036,412	Q4 2024 Added 2.73%
CLDX Celldex Therapeutics, Inc.	$1.06B	$89.9 Million 0.01% of portfolio	3,557,136	Q4 2024 Added 23.5%
CNTA Centessa Pharmaceuticals PLC	$1.61B	$89.9 Million 0.01% of portfolio	5,364,392	Q4 2024 Added 14.65%
VRNA Verona Pharma PLC	$3.91B	$85.2 Million 0.01% of portfolio	1,833,532	Q4 2024 Added 37.32%
KRYS Krystal Biotech, Inc.	$3.93B	$79.8 Million 0.01% of portfolio	509,459	Q4 2024 Added 16.25%
AGIO Agios Pharmaceuticals, Inc.	$1.82B	$79.6 Million 0.01% of portfolio	2,423,537	Q4 2024 Reduced 14.44%
ARVN Arvinas, Inc.	$974M	$78.7 Million 0.01% of portfolio	4,103,011	Q4 2024 Added 6.47%
IMCR Immunocore Holdings PLC	$1.3B	$64.5 Million 0.01% of portfolio	2,187,530	Q4 2024 Added 1.38%
INCY Incyte Corp	$15.7B	$63.1 Million 0.01% of portfolio	913,708	Q4 2024 Added 50.17%
WVE Wave Life Sciences Ltd.	$939M	$63.1 Million 0.01% of portfolio	5,098,866	Q4 2024 Added 63.08%
DNLI Denali Therapeutics Inc.	$2.87B	$62.3 Million 0.01% of portfolio	3,058,615	Q4 2024 Added 6.58%
ZLAB Zai Lab LTD	$2.84B	$61.7 Million 0.01% of portfolio	2,354,025	Q4 2024 Added 30.37%
PLRX Pliant Therapeutics, Inc.	$148M	$61 Million 0.01% of portfolio	4,634,486	Q4 2024 Reduced 4.14%
JANX Janux Therapeutics, Inc.	$1.52B	$59.4 Million 0.01% of portfolio	1,109,978	Q4 2024 Added 596.26%
EXEL Exelixis, Inc.	$11.3B	$58.8 Million 0.01% of portfolio	1,766,841	Q4 2024 Reduced 6.61%
MIRM Mirum Pharmaceuticals, Inc.	$1.84B	$58.8 Million 0.01% of portfolio	1,422,729	Q4 2024 Added 10.8%
HALO Halozyme Therapeutics, Inc.	$8.12B	$58.2 Million 0.01% of portfolio	1,218,326	Q4 2024 Reduced 4.11%
NRIX Nurix Therapeutics, Inc.	$829M	$56.7 Million 0.01% of portfolio	3,007,327	Q4 2024 Reduced 2.01%
DYN Dyne Therapeutics, Inc.	$720M	$56.6 Million 0.01% of portfolio	2,402,452	Q4 2024 Reduced 8.87%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.